A Phase 1, Double-Blind (Sponsor-Open), Placebo- And Active-Controlled, Single Dose, Crossover Study To Assess Antimineralocorticoid Activity Of Oral Pf-03882845 In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2011
At a glance
- Drugs PF 3882845; Spironolactone
- Indications Diabetic nephropathies
- Focus Pharmacodynamics; Pharmacokinetics
- 05 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Mar 2011 New trial record